GHRP-6

Occurs within 30–60 minutes of injection and persists for 2–4 hours. This is a direct result of ghrelin receptor activation. Manage by timing injections away from meals or planning caloric intake accordingly. Some users find this beneficial for bulking phases; others find it problematic.

Reported with chronic GH elevation from secretagogues. Results from fluid retention and nerve compression in the wrist. Onset is typically gradual (weeks to months). Manage with wrist splinting, NSAIDs, or dose reduction. Discontinue if symptoms worsen.

Related to fluid retention and nerve compression. Usually resolves with dose reduction or cycling off the peptide. Monitor for progression to carpal tunnel syndrome.

May result from rapid GH elevation and increased IGF-1 signalling. Typically mild and self-resolving. Manage with rest, NSAIDs, or dose adjustment.

Reported in some users, possibly related to fluid retention or rapid GH elevation. Usually mild and transient. Manage with hydration and over-the-counter analgesics.

Occurs shortly after injection, likely due to vasodilation from GH and cortisol release. Resolves within 30–60 minutes. No intervention required.

Local inflammatory response at the injection site. Minimise by rotating sites, using sterile technique, and allowing the solution to reach room temperature before injection. Apply ice if swelling occurs.

Reported occasionally, possibly related to rapid GH elevation or injection timing. Usually resolves within 1–2 hours. Inject on an empty stomach to reduce risk.

Chronic GHRP-6 use leads to receptor desensitisation, reducing GH response magnitude. Manage by cycling the peptide (e.g., 5 days on, 2 days off, or 8 weeks on, 4 weeks off). Alternating with other secretagogues (e.g., GHRP-2, ipamorelin) may help maintain responsiveness.

GHRP-6 stimulates cortisol release alongside GH. Chronic elevation may impair recovery and increase catabolic effects. Monitor cortisol levels if using long-term. Manage with adequate sleep, stress reduction, and cycling.

GHRP-6 stimulates prolactin release, though less potently than GH. Rarely clinically significant at research doses. Monitor if using high doses or long-term.

Results from repeated injections at the same site. Prevent by rotating injection sites systematically. Lipodystrophy is usually reversible if sites are rotated.

GH is counter-regulatory and typically raises blood glucose, but some users report transient hypoglycaemia, especially if fasted. Monitor blood glucose if diabetic or sensitive to hypoglycaemia. Inject with a small carbohydrate source available.